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Novel Homozygous Frameshift Mutation of EVER1
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Epidermodysplasia verruciformis (EV) is a rare genetic skin disease with an autosomal recessive trait, and the
patients have susceptibility to a specific group of human papillomavirus genotypes. Recently germline
mutations in EVER1/2 genes have been detected in EV patients with different ethnic origins. In this study, we
have applied PCR, single-stranded conformational polymorphism analysis, and sequencing as well as restriction
fragment length polymorphism analysis for identifying potential mutation(s) of EVER genes in an EV patient and
in the parents of Pakistani origin. A novel homozygous frameshift mutation (T base deletion at nucleotide
position 968 of DNA) has been detected in the EVER1 gene of the patient. The parents carried this mutated allele
in a heterozygous form. This is the third report on the presence of EVER1 mutations in an EV patient, and this
result supports better understanding, diagnosis, and genetic counseling of EV patients.
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INTRODUCTION
Epidermodysplasia verruciformis (EV) is a rare genoderma-
tosis with an autosomal recessive trait. The EV patients have
abnormal susceptibility to a specific group of human
papillomavirus (HPV) genotypes (Orth et al., 2001). The
infection with these EV-associated HPV genotypes contri-
butes to the development of flat wart like and pityriasis
versicolor like lesions, Bowen type squamous cell carcino-
mas in situ, and ultimately invasive squamous cell carcino-
mas (Orth, 1987).
More recently, EV genes, EVER1 and EVER2, were
identified; mutations of these genes are responsible for
development of EV disease. EVER1 and EVER2 genes are
located on chromosome 17q25. Complementary DNAs of
full-length EVER1 and EVER2 transcripts were characterized
from lymphoblastoid cell lines and from normal skin (Ramoz
et al., 2002). Two further case reports have confirmed the
presence of EVER1 or EVER2 mutations in EV patients (Tate
et al., 2004, Sun et al., 2005) and one article reported the
lack of mutation of these genes in an EV patient (Azzimonti
et al., 2005).
In this case report we describe the presence of a novel
frameshift mutation of the EVER1 gene in an EV patient and in
the parents.
CLINICAL HISTORY
This is a 34-year-old Pakistani man who presented to the
outpatient department with a history of multiple verrucous
lesions on his face, torso, and extremities that first appeared
at age 14. The patient’s parents are brother and sister and the
patient is the only family member affected. He is married to a
healthy, unrelated woman, and has one son who is
unaffected. The lesions on his face, chest, abdomen, and
back were brown and pink verrucous plaques resembling flat
warts. On his forearms and knees, he presented with multiple
verrucous papules and plaques resembling common warts.
He also presented with multiple pink and dark brown palmar
hyperkeratotic plaques. The patient had no other disorder and
was diagnosed with EV based on the clinical and histopatho-
logical findings of moderate hyperkeratosis and acanthosis
and with an irregular granular zone, occasional perinuclear
halos, and characteristic enlargement of the keratinocytes
(Figure 1). Biopsy specimens from this patient did not exhibit
features of squamous cell carcinoma or Bowen’s disease.
Before diagnosis of EV, the patient was presumed to have an
atypical presentation of psoriasis and was treated with
acitretin 10 mg daily for which he saw the best clinical
results. The patient stopped therapy owing to insomnia,
which he attributed to the medication. The patient was
subsequently treated with trials of topical tretinoin 0.1% or
oral isotretinoin 40 mg daily with only mild improvement.
Recently disease has worsened and the patient’s treatment
with acitretin therapy (10 mg daily by mouth) was again
administered.
Multiple HPV infections were detected in the wart
biopsies of the patient. One of the flat warts contained
HPV-17, and known but not fully characterized DL473 (NCBI
ID: 5830225) and SK3 (ID: 8650474) HPV DNA. The other
flat wart carried DL473 and SK3 HPV isolates. The common
wart contained HPV-17 DNA. Additionally the wart samples
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carried a novel HPV DNA isolate designated to GRT04
(NCBI-GenBank ID: DQ641480) which had 83% sequence
identity to HPV38 (ID: 1020234) in the L1 region.
RESULTS
The single-strand conformation polymorphism analysis in-
dicated the presence of a mutation in exon 9 of the EVER1
gene (data not shown). The sequencing of the PCR fragment
revealed a homozygous T base deletion at the nucleotide
position 968 of EVER1 complementary DNA (NCBI ID:
AY099356) (Figure 2a). The computer assisted open reading
frame analysis predicted that this frameshift mutation results
in a premature termination codon at nucleotide c.1045.
According to the rules for nomenclature the mutation can be
designated as c.968delT (L323fsX26) (den Dunnen and
Antonarakis, 2001). The computer assisted restriction map
analysis of the exon 9 specific PCR fragment revealed that the
mutation created a specific MspI restriction enzyme site. The
restriction fragment length polymorphism analysis using the
MspI enzyme confirmed the presence of c.968delT in the
patient (Figure 2b). Similar analysis indicated that the
patient’s parents are heterozygous for c.968delT (Figure 2b).
DISCUSSION
In our study, we found a homozygous frameshift mutation of
the EVER1 gene in a patient of Pakistani descent who was
born from consanguineous parents (Figure 2; Table 1). The
computer analysis of the mutation predicts a premature
termination codon at nucleotide c.1045. Although this
premature termination codon may trigger nonsense-mediated
messenger RNA decay, a well-established mechanism
involved in preventing translation of truncated proteins due
to premature termination codons, approximately 5–25% of
messenger RNA containing premature termination codon
escape nonsense-mediated messenger RNA decay suggesting
a low level of truncated EVER1 protein (approximately 350
amino acids long) with altered function may be expressed in
this patient (Kuzmiak and Maquat, 2006).
Although this is early evidence of the c.968delT
(p.L323fsX26) mutation, other EVER1 and EVER2 mutations
have been identified. Ramoz et al. (2002) discovered the
EVER1 and EVER2 genes, and identified nonsense mutations
in two Algerian and two Colombian consanguineous EV
families. This pioneering work was followed by the finding of
two new heterozygous mutations (combination of a splice
Figure 1. Flat wart biopsy from the patient’s back demonstrates histologic
features of EV. Note the moderate hyperkeratosis and acanthosis as well as
irregular granular zone, perinuclear halos, and intranuclear vacuoles
consistent with the diagnosis of EV. Bar¼ 100mm.
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Figure 2. Identification of a homozygous frameshift mutation in exon 9 of
the EVER1 gene. (a) The automated sequencing of the PCR fragment derived
from exon 9 of the EVER1 gene of the patient (P) detected a homozygous
thymine deletion at position 968 (c.968delT). The wild-type (WT) sequence is
also shown. (b) RFLP analysis of PCR fragment amplified from exon 9 of the
EVER1 gene utilizing MspI restriction enzyme. c.968delT created an MspI
cleavage site and the enzyme digestion resulted in 155- and 115-bp-sized
fragments of the 270-bp-sized PCR product derived from the patient (lane P)
and from the positive control (lane, PC). The positive control DNA was a
cloned PCR fragment from the patient containing the mutated allele with the T
deletion (pCR4-TOPO plasmid, Invitrogen Co). The deletion was verified by
sequencing in this positive control. The 270-bp-sized PCR fragment from
negative control DNA (lane, WT) was not digested by MspI enzyme. The
undigested 270 bp PCR fragment from a negative control (lane UD) is also
shown. A negative PCR reagent control (no DNA) (lane R), fx174 RF DNA
marker (Invitrogen Co. Carlsbad, CA) (lane S1) and 25 bp DNA ladder marker
(Invitrogen Co.) (lane S2) can be seen on the gel. The RFLP analysis also
served as a confirmation of the presence of the c.968delT mutation in the
family members. The digested PCR samples from the patient’s mother (M) and
father (F) showed three fragments (270, 155, and 115 bp sizes) indicating that
they are both c.968delT mutation heterozygotes.
Table 1. Summary of EVER1 mutations reported in EV
Mutation Position (cDNA) Exon IVS References
Nonsense 280 (C–T) 5 — Ramoz et al. (2002)
Nonsense 744 (C–A) 8 — Tate et al. (2004)
Splice site
(acceptor)
IVS8-2 (A–T) — 8 Tate et al. (2004)
Frameshift 968 (T deletion) 9 — This study
Nonsense 1726 (G–T) 14 — Ramoz et al. (2002)
cDNA, complemenatry DNA; EV, epidermodysplasia verruciformis; IVS,
intervening sequence.
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site and a nonsense mutation) in the EVER1 gene of a
Japanese EV patient (Table 1). Sun et al. (2005) reported a
novel homozygous nonsense mutation in the EVER2 gene of a
Chinese EV patient born from a consanguineous marriage.
Interestingly, a recent report could not find a mutation of the
EVER genes in an EV patient (Azzimonti et al., 2005),
suggesting a second genetic locus may be involved EV
disease pathogenesis (Ramoz et al., 2000).
Putative EVER1 and EVER2 proteins share 28.4% amino
acids and belong to the transmembrane channel gene family,
and are also designated as TMC6 and TMC8 (Keresztes et al.,
2003; Kurima et al., 2003). Both are integral membrane
proteins and are localized in the endoplasmic reticulum. The
role of EVER1 and EVER2 gene products in EV pathogenesis is
still unclear. They may be involved in controlling the HPV
pathogenesis in epidermal keratinocytes or play a role in the
innate or adaptive immune responses which may control the
clearance of EV-HPV-infected keratinocytes (Ramoz et al.,
2002).
In conclusion, we report a novel frameshift mutation of the
EVER1 gene in an EV patient of Pakistani descent. This
mutation study provides additional information to the under-
standing of the role of the EVER1 gene in EV pathogenesis.
The restriction fragment length polymorphism analysis can
serve as a quick screening procedure and may help with the
genetic counseling of the relatives within this EV family.
MATERIALS AND METHODS
Patients
A family with a sibling affected with EV disease was studied. The
parents had a consanguineous marriage. Blood samples were
obtained from the parents and from the sibling with EV disease.
Biopsies from two flat warts and a common wart of the EV patient
were taken for HPV testing. The patient and his parents were
recruited into the study after giving informed consent and this study
was conducted following Institutional Review Board (IRB) approval
and followed the Declaration of Helsinki Principles.
Histology
Tissue from flat wart biopsies were fixed in formalin, embedded in
paraffin, sectioned onto glass slides, and stained with hematoxylin
and eosin.
DNA extraction
DNA was extracted from the whole-blood samples of the parents,
peripheral blood mononuclear cells, and the biopsies of the patient
using a DNA extraction kit (Puregene, Gentra Systems Inc,
Minneapolis, MN). The quality of the DNA extracted for PCR
procedures was assessed by amplification of the reference control
gene b-globin (Resnick et al., 1990).
Determination of HPV sequences by PCR and sequencing
The nested PCR method was utilized as previously described by
Berkhout et al. (1995). For the first step, PCR amplification was
performed using two degenerate consensus primers termed CP65
and CP70, with annealing sites located in the L1 open-reading
frame. The CP65/70 primer set amplifies the complete set of EV-HPV
types. For the second PCR step, two nested primers termed CP66 and
CP69 were used. Isolation and sequence analysis of HPV-PCR
products were performed as described earlier (de Oliveira et al.,
2004).
Detection of mutation within EVER1 and EVER2 genes
PCR fragments for the exons of EVER1 and EVER2 genes of the EV
patient were amplified individually using sequence information as
described earlier (Ramoz et al., 2002). Additional sequence
information of primers and gene maps was kindly provided by
Gerard Orth and Michel Favre (Department of Virology, Institute
Pasteur, Paris, France). For screening of mutations, single-strand
conformation polymorphism analysis of the exon specific PCR
fragments was utilized via the Genephor DNA Separation System
and Precast GeneGel Excel 12.5/24 gels (GE Healthcare, Piscat-
away, NJ). The gels were silver-stained applying the Plus One DNA
silver-staining kit and Processor-Plus instrument (GE Healthcare).
After the single-strand conformation polymorphism screening a
mutation was verified with automated sequencing of the PCR
fragment derived from the exon 9 of EVER1 gene (ABI Prism 3100
Genetic Analyzer, Applied BioSystems, Foster City, CA). The
sequencing reactions were performed by the Sequencing Core
Facility of the Department of Microbiology & Molecular Genetics,
UT-Medical School, Houston.
Restriction fragment length polymorphism analysis and
confirmation of the mutation identified by sequencing within
the exon 9 of the EVER1 gene from the patient and the parents
The sequencing indicated the presence of a homozygous T base
deletion in exon 9 of the EVER1 complementary DNA (nucleotide
position: 968) from the patient (Figure 2). The restriction enzyme
map of this gene region was analyzed by GeneRunner for Windows,
version 3.05, software (Hastings Software Inc., Hastings, NY). The
evaluation indicated that the mutation will create a specific MspI
cleavage site. The PCR fragments derived from the patient and
parents were digested with MspI. The digested PCR products were
run on 2.5% SeaKem LE agarose (Cambrex BioScience Rockland Inc,
Rockland, ME) gel electrophoresis and visualized on a UV
transilluminator (Figure 2).
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